In this month's Connection newsletter:
- Explore resources related to multiple sclerosis for Multiple Sclerosis Awareness Month in March
- Join us in Houston for AMCP Annual to network and learn
- Discover the latest ICER Reports available on FormularyDecisions
- Participate in survey and feedback opportunities via the MyInsights Program
- Register for a diverse lineup of upcoming webinars
Multiple Sclerosis Awareness Month
March is Multiple Sclerosis Awareness Month. Multiple sclerosis (MS) is a chronic, inflammatory, and neurodegenerative disorder of the central nervous system affecting 2.9 million people worldwide.
According to the latest edition of the Atlas of MS, there are more than 900,000 people living with MS in the United States (US), with 24,924 new people diagnosed each year.1 While up to 10% of patients experience initial clinical disease manifestation before the age of 18 years,2 recent epidemiological evidence indicates an increasing incidence of the disease after the age of 50 years.3
Utilize our resources below to access the latest information:
Utilize Product Snapshots, ICER reports, eDossiers, and Metasearch Results to access the latest information on multiple sclerosis. A sample of Metasearch Results articles from the multiple sclerosis disease page is included below.
Product Snapshots
Leverage Product Snapshots on products indicated for multiple sclerosis– created by clinical pharmacists at ForHealth Consulting (formerly Commonwealth Medicine), the healthcare consulting and operations division of the University of Massachusetts Chan Medical School |
ICER Reports
Peruse the latest ICER report on multiple sclerosis from November 19, 2024 |
eDossiers
Submit an eRequest for access to eDossiers for products associated with multiple sclerosis |
This announcement is an advertisement paid for by Biogen. FormularyDecisions is not providing a product recommendation. Readers should review all available materials related to the product and indication discussed herein before making any decision related to the purchase or use of the product. Any questions about such products must be directed to the biopharma company.
Houston! We Have a Solution..
Join us to learn more about how your colleagues are leveraging FormularyDecisions and pre-approval information in their product review process while enjoying a tasty treat. Space is limited - RSVP today!
Session: Houston! We Have a Solution: Network and Learn with FormularyDecisions
Date: Wednesday, April 2, 2025
Time: 1:30-2:30pm CT
Location: George R. Brown Convention Center, Room 360B
Session: Houston! We Have a Solution: Network and Learn with FormularyDecisions
Date: Wednesday, April 2, 2025
Time: 1:30-2:30pm CT
Location: George R. Brown Convention Center, Room 360B
If you are unable to attend the networking event, stop by the FormularyDecisions kiosk and photo booth in the AMCP registration area or the Cencora booth #409 in the Expo Hall to meet some of our dedicated team members. Click here to discover the full extent of Cencora’s participation at AMCP Annual.
Did you know?
Enhance your knowledge with ICER Reports
The Institute for Clinical and Economic Review (ICER) provides independent assessments of the clinical effectiveness and economic value of healthcare interventions, including drugs and medical technologies. Their evidence reports include cost-effectiveness analyses, potential budget impact, and other perspectives that capture insights surrounding product value. The most recently posted ICER reports can be found on the FormularyDecisions Homepage, and you can view the full list here.
MyInsights Program Survey Opportunities Available
Product surveys are an important way to share your insights with biopharma companies. Not only does your feedback communicate specific content requests to biopharma companies (eg, comparative effectiveness analysis, real-world evidence) so that they are more likely to post helpful files to FormularyDecisions, but it also helps biopharma companies identify potential evidence gaps that can be filled over time.
Log into FormularyDecisions to view all survey and feedback opportunities available. Earn points for completing surveys that can be redeemed in the form of gift cards and/or donated to a charity.
Below are links to the Product Pages for surveys that are at the top of the list of all available surveys when you sort by “Most Recent” on FormularyDecisions.
Status |
Product page with survey opportunities |
|
Pre-approvala |
|
|
FDA-approvedb |
FreeStyle Libre 2 and Freestyle Libre 38 |
Don’t forget to also check out the following survey opportunities that may be leaving soon.
Status |
Product page with survey opportunities |
|
Pre-approvala |
|
|
FDA-approvedb |
BIZENGRI® (zenocutuzumab-zbco)24 PAXLOVID™ (nirmatrelvir and ritonavir)29 |
AMCP Webinar hosted by FormularyDecisions®
The missing PIEce: Best practices for implementing Pre-approval Information Exchange (PIE) in a payer communication plan
Date: Friday, March 14, 2024
Time: 2:00-3:00 pm ET
Join us for an interactive, engaging, and informative discussion as we dive into the evolving landscape of pre-approval information exchange (PIE). Our diverse panel of biopharma and market access and communication experts will guide you through a live session filled with valuable insights and strategies for engaging healthcare decision-makers with pre-approval information. We will explore opportunities and innovative solutions for leveraging PIE when collaborating with stakeholders.
Time: 2:00-3:00 pm ET
Join us for an interactive, engaging, and informative discussion as we dive into the evolving landscape of pre-approval information exchange (PIE). Our diverse panel of biopharma and market access and communication experts will guide you through a live session filled with valuable insights and strategies for engaging healthcare decision-makers with pre-approval information. We will explore opportunities and innovative solutions for leveraging PIE when collaborating with stakeholders.
Key learnings
- Understand the latest trends in how pre-approval information exchange (PIE) is leveraged by biopharma companies to communicate with healthcare decision-makers through various channels.
- Explore the impact of effective PIE strategies on stakeholder engagement and decision-making.
Click below for webinar details and to register through the AMCP website:
Cencora | NASP Webinar
Enhancing Specialty Drug Review and Formulary Insights
Date: Tuesday, March 25th, 2025
Time: 1:00-2:00 pm ET
FormularyDecisions | Cencora, in partnership with The National Association of Specialty Pharmacy, is pleased to announce a webinar, where you'll receive an overview of FormularyDecisions®, an online platform that supports the exchange of information between healthcare decision-makers and biopharma companies to streamline the product review process. This resource provides healthcare decision-makers complimentary access to evidence on more than 3,900 pipeline and FDA-approved products.
Time: 1:00-2:00 pm ET
FormularyDecisions | Cencora, in partnership with The National Association of Specialty Pharmacy, is pleased to announce a webinar, where you'll receive an overview of FormularyDecisions®, an online platform that supports the exchange of information between healthcare decision-makers and biopharma companies to streamline the product review process. This resource provides healthcare decision-makers complimentary access to evidence on more than 3,900 pipeline and FDA-approved products.
Key learnings
- Biosimilar Hub: an industry-recognized resource with an interactive chart of the US market landscape, a repository of state substitution laws, and a biosimilar indication tool
- Formulary Coverage Insights Tool: pharmacy and medical coverage data on formulary placement of hundreds of products
- Product Snapshots: curated pre-approval product information, clinical trial summaries, and P&T considerations created by clinical pharmacists
AMCP PIE Webinar
UGN-102 Pre-Approval Information Exchange (PIE) Presentationa
Date: Wednesday, March 26, 2025
Time: 2:00-3:00 pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
This PIE webinar is sponsored by UroGen Pharma, Inc. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision-makers and biopharma companies.
Click below for webinar details and to register:
Time: 2:00-3:00 pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
This PIE webinar is sponsored by UroGen Pharma, Inc. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision-makers and biopharma companies.
Click below for webinar details and to register:
References:
1. MS International Federation. Factsheet: United States of America. Accessed February 24, 2025. https://www.atlasofms.org/fact-sheet/united-states-of-america
2. Yan K, Balijepalli C, Desai K, Gullapalli L, Druyts E. Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis. Mult Scler Relat Disord. 2020;44:102260. doi:10.1016/j.msard.2020.102260
3. Prosperini L, Lucchini M, Ruggieri S, et al. Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry. 2022 Apr 27:jnnp-2022-329049. doi:10.1136/jnnp-2022-329049
4. de Mol CL, Lamballais S, Muetzel R, et al. Environmental multiple sclerosis (MS) risk factors, genetic MS risk, and brain development in a general paediatric population. J Neurol Neurosurg Psychiatry. Published online December 10, 2024. doi:10.1136/jnnp-2024-335053
5. Olek M, et al. UpToDate.com. Overview of disease-modifying therapies for multiple sclerosis. Literature review current through: January 2025. This topic last updated: January 6, 2025. Accessed February 24, 2025.
6. Salter A, Lancia S, Kowalec K, Fitzgerald KC, Marrie RA. Comorbidity and disease activity in multiple sclerosis. JAMA Neurol. 2024;81(11):1170-1177. doi:10.1001/jamaneurol.2024.2920
7. Medscape. Highlights and Insights from the Consortium of Multiple Sclerosis Centers (CMSC) 2024. Accessed February 24, 2025. https://www.medscape.com/viewarticle/999690?form=fpf
8. FreeStyle Libre 2 and Freestyle Libre 3. Abbott; 2024.
9. Isturisa. Prescribing information. Recordati Rare Diseases, Inc.; 2023. Accessed February 24, 2025. https://www.recordatirarediseases.com/sites/www.recordatirarediseases.com/files/inline-files/Isturisa-Prescribing-Information-Current.pdf
10. Jakafi. Prescribing information. Incyte Corporation; 2023. Accessed February 24, 2025. https://www.jakafi.com/jakafi-prescribing-information
11. Journavx. Prescribing information. Vertex Pharmaceuticals Incorporated; 2025. Accessed February 24, 2025. https://pi.vrtx.com/files/uspi_suzetrigine.pdf
12. Kisunla. Prescribing information. Eli Lilly and Company; 2024. Accessed February 24, 2025. https://pi.lilly.com/us/kisunla-uspi.pdf
13. Monjuvi. Prescribing information. Incyte Corporation; 2024. Accessed February 24, 2025. https://www.monjuvi.com/pi/monjuvi-pi.pdf
14. Niktimvo. Prescribing information. Incyte Corporation; 2025. Accessed February 24, 2025. https://www.niktimvo.com/niktimvo-prescribing-information
15. Omvoh. Eli Lilly and Company; 2025. Accessed February 24, 2025. https://uspl.lilly.com/omvoh/omvoh.html#pi
16. Revuforj. Prescribing information. Syndax Pharmaceuticals, Inc.; 2024. Accessed February 24, 2025. https://cms.syndax.com/wp-content/uploads/Revuforj-full-prescribing-info.pdf
17. Stivarga. Prescribing information. Bayer HealthCare Pharmaceuticals; 2020. Accessed February 24, 2025. https://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf
18. Velsipity. Prescribing information. Pfizer Inc.; 2024. Accessed February 24, 2025. https://labeling.pfizer.com/ShowLabeling.aspx?id=19776
19. Veltassa. Prescribing information. Vifor Pharma, Inc.; 2023. Accessed February 24, 2025. https://www.veltassa.com/hcp/pi
20. Xofigo. Prescribing information. Bayer HealthCare Pharmaceuticals; 2019. Accessed February 24, 2025. https://labeling.bayerhealthcare.com/html/products/pi/Xofigo_PI.pdf
21. Zepbound. Prescribing information. Eli Lilly and Company; 2024. Accessed February 24, 2025. https://pi.lilly.com/us/zepbound-uspi.pdf
22. Zeposia. Prescribing information. Bristol Myers Squibb; 2024. Accessed February 24, 2025. https://packageinserts.bms.com/pi/pi_zeposia.pdf
23. Benlysta. Prescribing information. GlaxoSmithKline plc; 2024. Accessed February 24, 2025. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF
24. Bizengri. Prescribing information. Partner Therapeutics, Inc.; 2025. Accessed February 24, 2025. https://www.bizengri.com/pdf/pi.pdf
25. Comirnaty. Prescribing information. Pfizer, Inc.; 2024. Accessed February 24, 2025. https://labeling.pfizer.com/ShowLabeling.aspx?id=16351&format=pdf
26. Crenessity. Prescribing information. Neurocrine Biosciences, Inc.; 2024. Accessed February 24, 2025. https://pi.neurocrine.com/crenessity/CRENESSITY-Full-US-Prescribing-Information.pdf
27. Jardiance. Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.; 2023. Accessed February 24, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf
28. Livdelzi prescribing information. Gilead Sciences, Inc.; 2024. Accessed February 24, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf
29. Paxlovid. Prescribing information. Pfizer Inc.; 2023. Accessed February 24, 2025. https://labeling.pfizer.com/ShowLabeling.aspx?id=19599
30. Tarpeyo. Prescribing information. Calliditas Therapeutics; 2024. Accessed February 24, 2025. https://www.tarpeyo.com/prescribinginformation.pdf
31. Tecelra. Prescribing information. Adaptimmune LLC; 2024. Accessed February 24, 2025. https://d1io3yog0oux5.cloudfront.net/_a2f385b85806f15c0d899c699b298e41/adaptimmune/files/documents/TECELRA_Final_PI.pdf
32. Vanflyta. Prescribing information. Daiichi Sankyo, Inc.; 2024. Accessed February 24, 2025. https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Vanflyta&inline=true
33. Xospata. Prescribing information. Astellas Pharma US, Inc.; 2022. Accessed February 24, 2025. https://astellas.us/docs/xospata.pdf
34. Xphozah. Prescribing information. Ardelyx Inc.; 2023. Accessed February 24, 2025. https://ardelyx.com/XPHOZAH-Prescribing-Information.pdf
35. Yescarta. Prescribing information. Kite Pharma, Inc.; 2024. Accessed February 24, 2025. https://www.fda.gov/media/108377/download
a The products listed are in the clinical evaluation stage and have not been approved for use by the FDA. The safety and efficacy of these products have not been established. FormularyDecisions is providing this information to alert you to the status of this product and is not promoting this product generally or otherwise recommending this product for use in the treatment of any disease or inclusion on any formulary for which it has not yet been approved. Any questions about such products must be directed to the biopharma companies. The availability of this product information follows the guidance outlined in the Pre-approval Information Exchange Act of 2022 (Section 810 of H.R. 7667).
b The material is being shared to inform you of the availability of information on FormularyDecisions. In providing this information, FormularyDecisions is not promoting any products mentioned, making claims about risks or benefits, or otherwise recommending any product in general or for any patient or formulary. For complete information about the indications, risks, and benefits of any product, please consult appropriate clinical and safety information, including the complete product label and important safety information. All prescribing decisions and/or coverage decisions should be made independently by individuals with appropriate experience in reliance on their independent judgement.
FormularyDecisions is owned and operated by Xcenda L.L.C., which is a subsidiary of Cencora, a global pharmaceutical sourcing and distribution services company.
The contents of this communication are non-promotional and intended exclusively for healthcare decision-makers, formulary committees, and other similar entities responsible for selecting healthcare products for coverage or reimbursement. Do not forward this communication. FormularyDecisions strongly encourages our members to review all available information about a particular product, including but not limited to the product label, and to rely on their experience and expertise in making decisions about coverage or prescribing.